-+ 0.00%
-+ 0.00%
-+ 0.00%

Sutro Biopharma doses first patient in Phase 1 trial of STRO-006 for advanced solid tumors

PUBT·10/21/2026 12:05:38
Listen to the news
Sutro Biopharma doses first patient in Phase 1 trial of STRO-006 for advanced solid tumors
  • Sutro Biopharma dosed the first patient in a Phase 1 trial of STRO-006 for adults with advanced or metastatic solid tumors.
  • The ITGB6-targeting antibody-drug conjugate is its second wholly owned ADC to enter clinical testing in less than a year.
  • The trial will assess safety, drug behavior in the body and preliminary antitumor activity; initial clinical data are expected in late 2027.
  • Preclinical studies showed sustained antitumor activity with minimal target-related toxicity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210800PRIMZONEFULLFEED9849893) on October 21, 2026, and is solely responsible for the information contained therein.